secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115296
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Q3 loss narrows to $9.0M; YUPELRI sales up 9%; SVP R&D to depart Feb 2024
-------------------------------------------------------------------------

- GAAP net loss from continuing ops $9.0M vs $16.0M prior year; non-GAAP loss $0.7M (improved from $7.1M).
- YUPELRI net sales $58.3M (up 9% YoY, 6% QoQ); implied 35% share $20.4M.
- Richard Graham, SVP R&D, to depart Feb 29, 2024; part-time from Jan 1; Áine Miller promoted to SVP Development.
- Share buybacks $30.8M in Q3; $294.6M total; $30.4M remaining; program expected to complete by year-end 2023.
- PIFR-2 study enrollment complete; top-line data Jan 2024. CYPRESS last patient enrollment H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/tm2330011d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer